Effect of a proton pump inhibitor on postprandial gastric volume, emptying and symptoms in healthy human subjects: A pilot study

A. B M Grudell, Michael Camilleri, D. D. Burton, D. A. Stephens

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Background: In consensus guidelines, proton pump inhibitors (PPIs) are recommended for the treatment of functional dyspepsia. It is unclear whether PPIs change gastric volume or emptying. Aim: To assess the effect of a PPI, rabeprazole, on gastric volume and emptying and postprandial symptoms. Methods: In a double-blind, parallel-group placebo-controlled trial, 13 healthy participants were randomized to rabeprazole, 20 mg b.d., or placebo. On day 3, fasting gastric volume was measured using intravenous 99mTc- pertechnate and single photon emission computed tomography (SPECT). After the last dose of study medication, an 111In-chloride egg meal (300 kcal) was ingested, and postprandial gastric volume and emptying were measured by SPECT. Symptom ratings using a visual analogue scale (fullness, nausea, bloating, abdominal pain, aggregate score) were obtained at baseline and 15, 30, 45, 60 and 75 min postprandially. Group comparisons were performed using Mann-Whitney rank sum test. Results: There were no statistically significant differences in gastric volume or emptying in the two groups. However, there was a borderline increase in gastric volume with rabeprazole compared with placebo. Rabeprazole treatment reduced aggregate postprandial symptoms, particularly fullness, 30 min after the meal (P = 0.01). Conclusions: In healthy participants, rabeprazole, 20 mg b.d., did not significantly change gastric emptying, but reduced symptoms and had a borderline effect on gastric volume postprandially. The mechanism of reduced postprandial symptoms with a PPI requires further study.

Original languageEnglish (US)
Pages (from-to)1037-1043
Number of pages7
JournalAlimentary Pharmacology and Therapeutics
Volume24
Issue number7
DOIs
StatePublished - Oct 2006

Fingerprint

Rabeprazole
Proton Pump Inhibitors
Gastric Emptying
Stomach
Healthy Volunteers
Placebos
Single-Photon Emission-Computed Tomography
Meals
Dyspepsia
Nonparametric Statistics
Visual Analog Scale
Nausea
Abdominal Pain
Ovum
Chlorides
Fasting
Consensus
Guidelines
Therapeutics

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Effect of a proton pump inhibitor on postprandial gastric volume, emptying and symptoms in healthy human subjects : A pilot study. / Grudell, A. B M; Camilleri, Michael; Burton, D. D.; Stephens, D. A.

In: Alimentary Pharmacology and Therapeutics, Vol. 24, No. 7, 10.2006, p. 1037-1043.

Research output: Contribution to journalArticle

@article{c88699be052a4899944558ac8f19bbd1,
title = "Effect of a proton pump inhibitor on postprandial gastric volume, emptying and symptoms in healthy human subjects: A pilot study",
abstract = "Background: In consensus guidelines, proton pump inhibitors (PPIs) are recommended for the treatment of functional dyspepsia. It is unclear whether PPIs change gastric volume or emptying. Aim: To assess the effect of a PPI, rabeprazole, on gastric volume and emptying and postprandial symptoms. Methods: In a double-blind, parallel-group placebo-controlled trial, 13 healthy participants were randomized to rabeprazole, 20 mg b.d., or placebo. On day 3, fasting gastric volume was measured using intravenous 99mTc- pertechnate and single photon emission computed tomography (SPECT). After the last dose of study medication, an 111In-chloride egg meal (300 kcal) was ingested, and postprandial gastric volume and emptying were measured by SPECT. Symptom ratings using a visual analogue scale (fullness, nausea, bloating, abdominal pain, aggregate score) were obtained at baseline and 15, 30, 45, 60 and 75 min postprandially. Group comparisons were performed using Mann-Whitney rank sum test. Results: There were no statistically significant differences in gastric volume or emptying in the two groups. However, there was a borderline increase in gastric volume with rabeprazole compared with placebo. Rabeprazole treatment reduced aggregate postprandial symptoms, particularly fullness, 30 min after the meal (P = 0.01). Conclusions: In healthy participants, rabeprazole, 20 mg b.d., did not significantly change gastric emptying, but reduced symptoms and had a borderline effect on gastric volume postprandially. The mechanism of reduced postprandial symptoms with a PPI requires further study.",
author = "Grudell, {A. B M} and Michael Camilleri and Burton, {D. D.} and Stephens, {D. A.}",
year = "2006",
month = "10",
doi = "10.1111/j.1365-2036.2006.03102.x",
language = "English (US)",
volume = "24",
pages = "1037--1043",
journal = "Alimentary Pharmacology and Therapeutics",
issn = "0269-2813",
publisher = "Wiley-Blackwell",
number = "7",

}

TY - JOUR

T1 - Effect of a proton pump inhibitor on postprandial gastric volume, emptying and symptoms in healthy human subjects

T2 - A pilot study

AU - Grudell, A. B M

AU - Camilleri, Michael

AU - Burton, D. D.

AU - Stephens, D. A.

PY - 2006/10

Y1 - 2006/10

N2 - Background: In consensus guidelines, proton pump inhibitors (PPIs) are recommended for the treatment of functional dyspepsia. It is unclear whether PPIs change gastric volume or emptying. Aim: To assess the effect of a PPI, rabeprazole, on gastric volume and emptying and postprandial symptoms. Methods: In a double-blind, parallel-group placebo-controlled trial, 13 healthy participants were randomized to rabeprazole, 20 mg b.d., or placebo. On day 3, fasting gastric volume was measured using intravenous 99mTc- pertechnate and single photon emission computed tomography (SPECT). After the last dose of study medication, an 111In-chloride egg meal (300 kcal) was ingested, and postprandial gastric volume and emptying were measured by SPECT. Symptom ratings using a visual analogue scale (fullness, nausea, bloating, abdominal pain, aggregate score) were obtained at baseline and 15, 30, 45, 60 and 75 min postprandially. Group comparisons were performed using Mann-Whitney rank sum test. Results: There were no statistically significant differences in gastric volume or emptying in the two groups. However, there was a borderline increase in gastric volume with rabeprazole compared with placebo. Rabeprazole treatment reduced aggregate postprandial symptoms, particularly fullness, 30 min after the meal (P = 0.01). Conclusions: In healthy participants, rabeprazole, 20 mg b.d., did not significantly change gastric emptying, but reduced symptoms and had a borderline effect on gastric volume postprandially. The mechanism of reduced postprandial symptoms with a PPI requires further study.

AB - Background: In consensus guidelines, proton pump inhibitors (PPIs) are recommended for the treatment of functional dyspepsia. It is unclear whether PPIs change gastric volume or emptying. Aim: To assess the effect of a PPI, rabeprazole, on gastric volume and emptying and postprandial symptoms. Methods: In a double-blind, parallel-group placebo-controlled trial, 13 healthy participants were randomized to rabeprazole, 20 mg b.d., or placebo. On day 3, fasting gastric volume was measured using intravenous 99mTc- pertechnate and single photon emission computed tomography (SPECT). After the last dose of study medication, an 111In-chloride egg meal (300 kcal) was ingested, and postprandial gastric volume and emptying were measured by SPECT. Symptom ratings using a visual analogue scale (fullness, nausea, bloating, abdominal pain, aggregate score) were obtained at baseline and 15, 30, 45, 60 and 75 min postprandially. Group comparisons were performed using Mann-Whitney rank sum test. Results: There were no statistically significant differences in gastric volume or emptying in the two groups. However, there was a borderline increase in gastric volume with rabeprazole compared with placebo. Rabeprazole treatment reduced aggregate postprandial symptoms, particularly fullness, 30 min after the meal (P = 0.01). Conclusions: In healthy participants, rabeprazole, 20 mg b.d., did not significantly change gastric emptying, but reduced symptoms and had a borderline effect on gastric volume postprandially. The mechanism of reduced postprandial symptoms with a PPI requires further study.

UR - http://www.scopus.com/inward/record.url?scp=33748665463&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33748665463&partnerID=8YFLogxK

U2 - 10.1111/j.1365-2036.2006.03102.x

DO - 10.1111/j.1365-2036.2006.03102.x

M3 - Article

C2 - 16984497

AN - SCOPUS:33748665463

VL - 24

SP - 1037

EP - 1043

JO - Alimentary Pharmacology and Therapeutics

JF - Alimentary Pharmacology and Therapeutics

SN - 0269-2813

IS - 7

ER -